My husband left me at 60 to have a baby with a younger woman. Here's what it taught me. Man's dishwasher discovery prompts thousands to check their own appliances With the penny going away, what ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Madrigal Pharmaceuticals is ...

Madrigal Pharmaceuticals (MDGL) is back on investors radar after Rezdiffra s early launch exceeded expectations, putting the MASH therapy on a path toward blockbuster level sales and reshaping the ...

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equities hit a record high in the ...

Samuel Rocha IV is a journalist born and raised on San Antonio soul music, Spurs basketball and mini tacos. Despite being the country’s seventh-largest city, San Antonio, in South Texas, never feels ...

In case you've faced some hurdles solving the clue, Hairstyle for Antonio Madrigal, we've got the answer for you. Crossword puzzles offer a fantastic opportunity to engage your mind, enjoy leisure ...

Madrigal (shoulder) cleared waivers and opted for free agency Thursday. Madrigal missed the full 2025 campaign after undergoing surgery in February to repair a fractured left shoulder. The infielder, ...

Madrigal Pharmaceuticals' Rezdiffra generated sales of $287 million in the third quarter for a 35% sequential jump from Q2. In just its fifth full quarter on the market, the world’s first treatment ...

Madrigal Pharmaceuticals is reiterated as a Strong Buy, driven by Rezdiffra's rapid US launch and recent European approval. Q2 2025 saw Rezdiffra sales reach $213M and >23,000 patients, with Q3 ...

Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...

Madrigal Pharmaceuticals (NASDAQ:MDGL) has received conditional marketing approval from the European Commission for Rezdiffra (resmetirom) for non-cirrhotic metabolic dysfunction-associated ...

Madrigal Pharmaceuticals is paying $120 million upfront for a preclinical GLP-1 receptor agonist that the biopharma plans to pair up with its approved fatty liver disease med Rezdiffra. The GLP-1 drug ...